Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Coriat, Romain, Gouya, Hervé, Mir, Olivier, Ropert, Stanislas, Vignaux, Olivier, Chaussade, Stanislas, Sogni, Philippe, Pol, Stanislas, Blanchet, Benoit, Legmann, Paul, Goldwasser, François
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3038868/
https://ncbi.nlm.nih.gov/pubmed/21340026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0016978
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados